| Recruitment status | Completed |
| Unique ID issued by UMIN | UMIN000020989 |
| Receipt No. | R000024230 |
| Official scientific title of the study | Comparison of the effect of 20mg Vonoprazan,30mg,Lansoprazole and 20mg Famotidine on intragastric pH: A three-way crossover study |
| Date of disclosure of the study information | 2016/02/22 |
| Last modified on | 2018/02/14 (Ver. 6) |
| Basic information | ||
| Official scientific title of the study | Comparison of the effect of 20mg Vonoprazan,30mg,Lansoprazole and 20mg Famotidine on intragastric pH: A three-way crossover study | |
| Title of the study (Brief title) | Comparison of the effect of 20mg Vonoprazan,30mg,Lansoprazole and 20mg Famotidine on intragastric pH | |
| Region |
|
|
| Condition | ||
| Condition | reflux esophagitis | |
| Classification by specialty |
|
|
| Classification by malignancy | Others | |
| Genomic information | YES | |
| Objectives | |
| Narrative objectives1 | The ideal medication for treatment of acid related diseases should have a rapid onset of action to promote hemostasis and symptoms.
No studies have compared directly the intragastric pH of Vonoprazan that is a new class of proton pomp inhibitor (PPI), Lansoprazole and Famotidine |
| Basic objectives2 | Pharmacodynamics |
| Basic objectives -Others | |
| Trial characteristics_1 | |
| Trial characteristics_2 | |
| Developmental phase | |
| Assessment | |
| Primary outcomes | intragastric pH by pH meter attached to the antimony pH electrode for 6 hour after administration |
| Key secondary outcomes | |
| Base | |
| Study type | Interventional |
| Study design | |
| Basic design | Cross-over |
| Randomization | Randomized |
| Randomization unit | Individual |
| Blinding | Open -no one is blinded |
| Control | Active |
| Stratification | |
| Dynamic allocation | |
| Institution consideration | |
| Blocking | |
| Concealment | |
| Intervention | ||
| No. of arms | 3 | |
| Purpose of intervention | Treatment | |
| Type of intervention |
|
|
| Interventions/Control_1 | Vonoprazan20mg-(washout period)-Lansoprazole30mg-(washout period)-Famotidine20mg | |
| Interventions/Control_2 | Lansoprazole30mg-(washout period)-Vonoprazan20mg-(washout period)-Famotidine20mg | |
| Interventions/Control_3 | Famotidine20mg-(washout period)-Lansoprazole30mg-(washout period)-Vonoprazan20mg | |
| Interventions/Control_4 | ||
| Interventions/Control_5 | ||
| Interventions/Control_6 | ||
| Interventions/Control_7 | ||
| Interventions/Control_8 | ||
| Interventions/Control_9 | ||
| Interventions/Control_10 | ||
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Male | |||
| Key inclusion criteria | Patient who fills everything the following
1) Helicobacter pylori-negative male Patient 2) Patient of 20 years or more 3) Patient who gives written informed consent |
|||
| Key exclusion criteria | The patient who collides with either the following assumes that it doesn't put it in to the examination
1) Drug allergy 2) Patient who took medicine that influences movement and function of digestive tract such as proton pump inhibitor, H2 blocker, and NSAIDs within 4 weeks |
|||
| Target sample size | 15 | |||
| Research contact person | |
| Name of lead principal investigator | Masahiko Inamori |
| Organization | Yokohama City University School of Medicine |
| Division name | Department of Medical Education |
| Address | 3-9 Fuku-ura, Kanazawa-ku, Yokohama, Japan |
| TEL | 045-787-2626 |
| inamorim@yokohama-cu.ac.jp | |
| Public contact | |
| Name of contact person | Hiroshi Iida |
| Organization | Yokohama City University School of Medicine |
| Division name | Department of Medical Education |
| Address | 3-9 Fuku-ura, Kanazawa-ku, Yokohama, Japan |
| TEL | 045-787-2800 |
| Homepage URL | |
| hiro0905@yokohama-cu.ac.jp | |
| Sponsor | |
| Institute | Yokohama City University School of Medicine Department of Medical Education |
| Institute | |
| Department | |
| Funding Source | |
| Organization | None |
| Organization | |
| Division | |
| Category of Funding Organization | Self funding |
| Nationality of Funding Organization | |
| Other related organizations | |
| Co-sponsor | |
| Name of secondary funder(s) | |
| Secondary IDs | |
| Secondary IDs | NO |
| Study ID_1 | |
| Org. issuing International ID_1 | |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | 横浜市立大学医学部 |
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Progress | |||||||
| Recruitment status | Completed | ||||||
| Date of protocol fixation |
|
||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date | |||||||
| Date of closure to data entry | |||||||
| Date trial data considered complete | |||||||
| Date analysis concluded | |||||||
| Related information | |
| URL releasing protocol | |
| Publication of results | Unpublished |
| URL releasing results | |
| Results | |
| Other related information | |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://upload.umin.ac.jp/cgi-open-bin/icdr_e/ctr_view.cgi?recptno=R000024230 |